Genome & Company (314130.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩3,900 (+0.26%) as of
Key statistics
- Market cap
- 176.19B
- Dividend yield
- 0.00%
- 52-week range
- 2,705.00 – 10,180.00
- Beta
- 0.28
- Revenue (TTM)
- 24.46B
- Profit margin
- -169.09%
- Volume
- 225.09k
About Genome & Company
Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea, Asia, Europe, South America, North America, and internationally. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors, as well as microbiome-based products, including therapeutics, cosmeceuticals, and dietary supplements. In addition, it has a partnership with US Scioto Biosciences for the development of SB-121, which targets disorders related to the gut-brain axis, such as Autism Spectrum Disorder (ASD), as well as disorders related to gut-injury, including Necrotizing Enterocolitis (NEC). The company was founded in 2015 and is headquartered in Suwon-si, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Suwon-si, South Korea
- Employees
- 96
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.